Brighter recruits expert to support the development and launch of Actiste.
In connection to the upcoming launch of Actiste®, Brighter’s new advisor Jorge C. Otero is an important link to the global pharmaceutical industry. Together with the company's management Jorge C. Otero will develop the go to market strategies for Actiste and evaluate additional business areas in which the product can be applied, in addition to diabetes.
Jorge C. Otero, MD, has an extensive and documented background in the pharmaceutical industry and has been a senior executive for clinical development and medical affairs at large pharmaceutical companies such as Eli Lilly, GlaxoSmithKline and Amgen.
“Brighter possesses an interesting IP portfolio that is not only valuable for insulin injections and treatment of diabetes, but also for treatment with other drugs. Although Actiste is developed primarily with diabetes treatment in mind, the final product could also be used in many other situations, such as monitoring in clinical trials or injecting and treatment of various biologicals”, says Jorge C. Otero.
Diabetes remains Brighter’s primary focus area for Actiste and Jorge will play a key role in the upcoming launch.
“Jorge has in-depth knowledge in the field of pharmaceutical development, but also on how to quickly reach out with a medical device on a global scale. He has a wide network in specific industry sectors, and we are very happy that he has already identified several new potential applications for Actiste”, says Truls Sjöstedt, Brighter's CEO and founder.
“We have come far in negotiations with a couple of Mobile Network Operators (“MNO”) who have a very strong foothold in Northern Europe and in the contract likely to be signed shortly, it will be possible for us to compile a clearer launch plan while gaining strong backing when Actiste is launched”, says Truls Sjöstedt.
In February Brighter announced that Northern Europe and Southeast Asia are the likely first markets to to be signed for subscription services of Actiste, Brighter’s integrated and connected devices for insulin-treated diabetics. Contracts are expected to be concluded during the first half in 2016.
When Jorge visited us in Stockholm we took the opportunity to interview him. In the video, which is published on Brighter's website, www.brighter.se, Jorge explains why connected devices such as Actiste is valuable, how connected tools can be helpful in clinical trials and how the patient's influence and control over their disease can be strengthened.
Questions? Please contact:
Henrik Norström, COO
Phone: 46 733 40 30 45
Truls Sjöstedt, CEO
Phone: 46 709 73 46 00
About Brighter AB (publ)
Brighter develops solutions for data-driven and mobile health services. Through its intellectual property and innovative tools, jDome® and Actiste®, the company creates a more efficient care chain with focus on the individual. The goal is to simplify, streamline and enhance the information flow of relevant and reliable data between the patient and health care professionals. Brighter is initially focused on diabetes care and care for the elderly, but there are opportunities in the future to operate on a broader level, spanning more diseases and treatment approaches. This is done through The Benefit Loop™, Brighter’s cloud-based service that continuously collects, analyzes and shares data on the user's terms.
The Company's shares are listed on NASDAQOMX First North/BRIG. Brighter’s Certified Adviser on Nasdaq OMX First North is Remium Corporate Finance +46 (0)8 – 454 32 76, CorporateFinance@remium.com, www.remium.com.